PriceTargets.com logo

NASDAQ:XCUR - Exicure Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.13
  • Forecasted Upside: 3,173.81 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.13 As of 05/27/2022 05:00 PM ET
+0.30 (1.20%)

This chart shows the closing price for XCUR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Exicure Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XCUR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XCUR

Analyst Price Target is $4.13
▲ +3,173.81% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Exicure in the last 3 months. The average price target is $4.13, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 3,173.81% upside from the last price of $0.13.

This chart shows the closing price for XCUR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Exicure. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/13/2021Chardan CapitalDowngradeBuy ➝ NeutralHigh
11/23/2021Chardan CapitalLower Price TargetBuy$7.00 ➝ $2.25Low
8/31/2021HC WainwrightReiterated RatingBuy$6.00Low
5/17/2021HC WainwrightLower Price TargetBuy$8.00 ➝ $6.00High
3/4/2021HC WainwrightReiterated RatingBuyHigh
12/18/2020BMO Capital MarketsInitiated CoverageOutperform$6.00High
12/9/2020HC WainwrightReiterated RatingBuyHigh
9/17/2020Chardan CapitalBoost Price TargetBuy$5.00 ➝ $7.00High
6/16/2020HC WainwrightReiterated RatingBuy$8.00Medium
6/4/2020GuggenheimReiterated RatingBuy$9.00Medium
6/4/2020LADENBURG THALM/SH SHReiterated RatingBuy$18.00Medium
5/15/2020HC WainwrightReiterated RatingBuy$8.00Medium
4/2/2020Chardan CapitalReiterated RatingBuy$5.00High
3/4/2020HC WainwrightReiterated RatingBuy$8.00High
3/4/2020Chardan CapitalReiterated RatingBuy$5.00High
12/24/2019HC WainwrightReiterated RatingBuy$8.00Medium
12/11/2019HC WainwrightReiterated RatingBuy$8.00High
11/27/2019GuggenheimInitiated CoverageBuy$9.00High
11/21/2019HC WainwrightReiterated RatingBuy$8.00Low
11/20/2019GuggenheimInitiated CoverageBuy$9.00Medium
11/6/2019HC WainwrightReiterated RatingBuyHigh
11/6/2019HC WainwrightInitiated CoverageBuyHigh
3/26/2019Chardan CapitalInitiated CoverageBuy$5.00Medium
7/11/2018LADENBURG THALM/SH SHInitiated CoverageBuy$18.00High
(Data available from 5/28/2017 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2021
  • 4 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 8 very negative mentions
Mentions as of
11/29/2021
  • 21 very positive mentions
  • 22 positive mentions
  • 8 negative mentions
  • 5 very negative mentions
Mentions as of
12/29/2021
  • 4 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2022
  • 1 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2022
  • 2 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/28/2022

Current Sentiment

  • 2 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Exicure logo
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $0.13
Low: $0.12
High: $0.13

50 Day Range

MA: $0.17
Low: $0.10
High: $0.31

52 Week Range

Now: $0.13
Low: $0.10
High: $1.98

Volume

9,714,691 shs

Average Volume

12,957,439 shs

Market Capitalization

$15.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Exicure?

The following Wall Street sell-side analysts have issued research reports on Exicure in the last year: Chardan Capital, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for XCUR.

What is the current price target for Exicure?

0 Wall Street analysts have set twelve-month price targets for Exicure in the last year. Their average twelve-month price target is $4.13, suggesting a possible upside of 3,173.8%.
View the latest price targets for XCUR.

What is the current consensus analyst rating for Exicure?

Exicure currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XCUR will outperform the market and that investors should add to their positions of Exicure.
View the latest ratings for XCUR.

How do I contact Exicure's investor relations team?

Exicure's physical mailing address is 2430 N. Halsted St., Chicago IL, 60614. The company's listed phone number is (847) 673-1700 and its investor relations email address is [email protected]x.com. The official website for Exicure is www.exicuretx.com. Learn More about contacing Exicure investor relations.